Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13801 - 13806 of 13806 in total
DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
Investigational
Investigational
Matched Iupac: … 4-{[4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}benzoic acid …
Matched Salts cas: … 1902123-72-1
Investigational
Matched Iupac: … N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide. People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort. Currently, most doctors who treat patients with PV will prescribe high-dose steroids...
Investigational
Matched Description: … Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. …
Experimental
Matched Iupac: … yl]oxy}oxolan-3-yl]oxidanesulfonic acid ... sulfooxy)-2,5-bis[(sulfooxy)methyl]-5-{[(2R,3R,4S,5R,6R)-3,4,5-tris(sulfooxy)-6-[(sulfooxy)methyl]oxan-2- …
Experimental
Matched Iupac: … (1R,3R,5S)-8-[(4-butoxyphenyl)methyl]-3-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-8-methyl-8-azabicyclo …
Displaying drugs 13801 - 13806 of 13806 in total